BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16647909)

  • 1. Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin.
    Banaszewska B; Duleba AJ; Spaczynski RZ; Pawelczyk L
    Am J Obstet Gynecol; 2006 May; 194(5):1266-72. PubMed ID: 16647909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
    Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
    Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
    Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
    Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study.
    Romualdi D; Costantini B; Campagna G; Lanzone A; Guido M
    Fertil Steril; 2008 Nov; 90(5):1826-33. PubMed ID: 18166189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of metformin in correcting hyperinsulinemia, menstrual irregularity and anovulation in polycystic ovary syndrome.
    Zafar S
    J Ayub Med Coll Abbottabad; 2005; 17(4):54-6. PubMed ID: 16599037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome.
    Krstevska B; Dimitrovski Ch; Pemovska G; Misevska S; Dimova Z; Simeonova S; Ahmeti I
    Prilozi; 2006 Jul; 27(1):57-66. PubMed ID: 16862066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial.
    Lord J; Thomas R; Fox B; Acharya U; Wilkin T
    BJOG; 2006 Jul; 113(7):817-24. PubMed ID: 16827766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
    Tan BK; Heutling D; Chen J; Farhatullah S; Adya R; Keay SD; Kennedy CR; Lehnert H; Randeva HS
    Diabetes; 2008 Jun; 57(6):1501-7. PubMed ID: 18375437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome.
    Ibáñez L; Ferrer A; Ong K; Amin R; Dunger D; de Zegher F
    J Pediatr; 2004 Jan; 144(1):23-9. PubMed ID: 14722514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome.
    Bridger T; MacDonald S; Baltzer F; Rodd C
    Arch Pediatr Adolesc Med; 2006 Mar; 160(3):241-6. PubMed ID: 16520442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
    Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
    AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities of fuel metabolism in the polycystic ovary syndrome.
    Wortsman J; Soler NG
    Obstet Gynecol; 1982 Sep; 60(3):342-5. PubMed ID: 6214733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and polycystic ovary syndrome.
    Lebinger TG
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):132-40. PubMed ID: 17940431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Alexandraki K; Piperi C; Aessopos A; Paterakis T; Katsikis I; Panidis D
    Metabolism; 2007 Jan; 56(1):129-34. PubMed ID: 17161235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of metformin therapy in patients with polycystic ovarian syndrome.
    Hasan JA; Memon GU
    J Coll Physicians Surg Pak; 2005 Nov; 15(11):712-5. PubMed ID: 16300709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome].
    Ma LK; Jin LN; Yu Q; Xu L
    Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):294-7. PubMed ID: 17673038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.